Compare MATW & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | ALT |
|---|---|---|
| Founded | 1850 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.1M | 573.8M |
| IPO Year | 1995 | 2005 |
| Metric | MATW | ALT |
|---|---|---|
| Price | $20.76 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 803.8K | ★ 4.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,795,737,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $20.21 | $2.56 |
| 52 Week High | $30.93 | $6.44 |
| Indicator | MATW | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 27.53 | 59.73 |
| Support Level | N/A | $3.18 |
| Resistance Level | $27.54 | $3.32 |
| Average True Range (ATR) | 0.70 | 0.14 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 16.64 | 82.29 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.